Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Erasca, Inc. (Nasdaq: ERAS) will participate in the 6th Annual Guggenheim Biotechnology Conference in New York, with the chairman and CEO, Jonathan E. Lim, and the CFO and chief business officer, David M. Chacko, taking part in a fireside chat and one-on-one investor meetings. The live audio webcast and archived replay of the event will be available on Erasca's website.
02/01/2024 - 08:00 AM
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual Guggenheim Biotechnology Conference being held at the St. Regis in New York, New York. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in a fireside chat on Thursday, February 8, 2024 at 11:00 am Eastern Time. Drs. Lim and Chacko will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events . An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events .
About Erasca At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact: Joyce Allaire LifeSci Advisors, LLC jallaire@lifesciadvisors.com
Source: Erasca, Inc.
What is the ticker symbol for Erasca, Inc.?
The ticker symbol for Erasca, Inc. is ERAS.
When and where is the 6th Annual Guggenheim Biotechnology Conference taking place?
The 6th Annual Guggenheim Biotechnology Conference is being held at the St. Regis in New York, New York.
Who will be participating in the fireside chat at the conference?
Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the fireside chat.
Where can the live audio webcast of the event be accessed?
The live audio webcast of the event will be available online at Erasca.com/events.
How long will the archived replay of the event be available?
An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
ERAS Rankings
#5244 Ranked by Stock Gains
ERAS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Country
US
City
San Diego
About ERAS
our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.